Huang SS, Heston WDW. Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?. Theranostics 2017; 7(7):1940-1941. doi:10.7150/thno.20284. https://www.thno.org/v07p1940.htm
Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the question of whether we can further increase the effectiveness of PSMA targeted therapy by adding an albumin-binding entity to low-molecular-weight agents
Citation styles
APA
Huang, S.S., Heston, W.D.W. (2017). Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?. Theranostics, 7(7), 1940-1941. https://doi.org/10.7150/thno.20284.
ACS
Huang, S.S.; Heston, W.D.W. Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?. Theranostics 2017, 7 (7), 1940-1941. DOI: 10.7150/thno.20284.
NLM
Huang SS, Heston WDW. Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?. Theranostics 2017; 7(7):1940-1941. doi:10.7150/thno.20284. https://www.thno.org/v07p1940.htm
CSE
Huang SS, Heston WDW. 2017. Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?. Theranostics. 7(7):1940-1941.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.